Navigation Links
EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers

ROCKVILLE, Md., April 19, 2007 /PRNewswire-FirstCall/-- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical results for MKC-1, its novel cell cycle inhibitor. The data were presented by EntreMed scientists at the American Association for Cancer Research (AACR) Annual Meeting being held this week in Los Angeles, California.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. In previous studies, MKC-1 demonstrated broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. MKC-1 has been shown to inhibit mitotic spindle formation, prevent chromosome segregation in the M-phase (mitosis) of the cell cycle, and induce apoptosis. These effects are consistent with mechanisms resulting from MKC-1 binding to multiple intracellular targets, including tubulin and the importin-beta proteins. The importin-beta family of proteins plays a critical role in nuclear transport and cell division.

In these studies, MKC-1 showed potent, dose-dependent activity against a variety of cell lines derived from cancers of human blood cells, and inhibited growth of primary cells derived from acute and chronic myelogenous leukemia (AML and CML) patients in vitro. MKC-1 was also shown to inhibit PI3-Kinase and mTOR pathways by inducing a dose-dependent reduction in the levels of the activated forms of the oncogenic kinases Akt and p70S6K. These signaling pathways are strongly linked to cancer proliferation and survival.

Additionally, MKC-1 showed enhanced activity with cytosine arabinoside (Ara-C) in combination studies in vitro when added either simultaneously or sequenti ally in an AML cell line. MKC-1, therefore, induces apoptosis in hematopoietic cell lines and patient samples through a complex mechanism involving arrest of the cell cycle and disruption of multiple oncogenic survival pathways.

Mark R. Bray, Ph.D., EntreMed's Vice President Research, commented on the results, "These data provide further evidence that MKC-1 disrupts multiple survival pathways in tumor cells, including the PI3-Kinase and mTOR signaling pathways. Our results indicate that MKC-1 causes cell cycle arrest and induces apoptosis both in leukemia cell lines and in leukemia patient samples."

Dr. Bray also commented, "These findings further support our plans to evaluate MKC-1 in leukemia patients, either as a single agent or in combination with other chemotherapeutic agents. MKC-1 is currently in Phase 2 trials for metastatic breast cancer and non-small cell lung cancer, as well as a Phase 1 clinical trial for leukemia. We plan to continue evaluating the clinical potential for MKC-1 in both solid and hematological tumors."

To view the poster presentation, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer a nd other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).


    Ginny Dunn

    EntreMed, Inc.

    Associate Director

    Corporate Communications &

    Investor Relations

    (240) 864-2643

CONTACT: Ginny Dunn, Associate Director, Corporate Commun ications &Investor Relations of EntreMed, Inc., +1-240-864-2643

Web site:

Ticker Symbol: (NASDAQ-NMS:ENMD)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
5. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:10/12/2015)... the United States . By early next year, ... the United States . By early next year, ... The University of Texas MD Anderson Cancer Center, Elekta and ... Tesla) MRI-guided linear accelerator in the United States ... a non-clinical capacity. Royal Philips (NYSE: PHG ...
(Date:10/12/2015)... -- Use this report to: - Learn ... the medical membrane devices market. - Analyze the present ... medical membrane devices market including hemodialyzers, membrane oxygenators, intravenous ... devices. - Gain information on newly approved products, recalls ... Use this report to: - Learn about the performance, ...
(Date:10/12/2015)... CRANBURY, N.J. , Oct. 12, 2015 /PRNewswire/ ... that a securities fraud class action complaint was ... of New Jersey.  The complaint alleges that officers and ... Securities Exchange Act of 1934 between September 15, 2015 ... misleading statements about Amicus Therapeutics, business prospects.  Amicus is ...
Breaking Medicine Technology:
(Date:10/12/2015)... , ... October 12, 2015 , ... Advera Health ... no charge to qualified Managed Care Organizations (MCOs) in order to provide health plans, ... into their decision making process. In addition, the DSM is also being offered to ...
(Date:10/12/2015)... ... October 12, 2015 , ... To ... announced its charitable donation to the National Breast Cancer Foundation. The National Breast ... by breast cancer through early detection, education, and support services. , The annual ...
(Date:10/12/2015)... ... ... Clara dentist , Dr. Alan Frame, shares his insight on today’s dental hygiene and the ... “I want each one of my patients to be at their optimum level of health, ... implants dentist , Dr. Frame. He mentions, "As the white paper mentions, oral health care ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... receive a Eugene Washington Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) ... the research community. , The project, entitled “Training Patients with Asthma to ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... secured a new corporate headquarters, located at 485 Madison Avenue, New York, NY ... and increased emphasis on cloud-based technology. , “Care to Care is a dynamic ...
Breaking Medicine News(10 mins):